Dynamic metrics-based biomarkers to predict responders to anti-PD-1 immunotherapy.

ABSTRACT:

Background

Anti-PD-1 immunotherapies have shown clinical benefit in multiple cancers, but response was only observed in a subset of patients. Predicting which patients will respond is an urgent clinical need, but current companion diagnosis based on PD-L1 IHC staining shows limited predictability.

Methods

A dynamic, metrics-based biomarker was developed to discriminate responders from non-responders for anti-PD-1 immunotherapy in B16F10 melanoma-bearing mice.

Results

Similar to patients, there was considerable heterogeneity in response to anti-PD-1 immunotherapy in mice. Compared with the control group, 45% of anti-PD-1 antibody-treated mice displayed improved survival (defined as responders) and the remainder only gained little, if any, survival benefit from PD-1 blo

SUBMITTER: Liu C 

PROVIDER: S-EPMC6353899 | biostudies-literature | 2019 Feb

REPOSITORIES: biostudies-literature